Hearing function in soft tissue sarcoma patients after treatment with carboplatin: a report from the Late Effects Surveillance System.

Abstract

The aim of this study was to analyse carboplatin-induced ototoxicity in a recent study trial. Twenty patients who had received carboplatin for the treatment of soft tissue sarcoma were investigated prospectively for ototoxicity in a multi-centre trial. Hearing function was tested by audiometry. All patients but one were treated with a cumulative dose of 1500 mg/m(2), the remaining with 500 mg/m(2). We evaluated the incidence and dependencies of hearing loss, and compared hearing thresholds to those of an untreated control group (n=60). Hearing thresholds in the carboplatin treated group were only marginally poorer compared with those of the control group. After carboplatin therapy no patient (0%; 95%-KI: 0-17%) had a hearing loss >20 dB. Hearing thresholds were not dependent on age, sex or cranial irradiation. We conclude that ototoxicity after carboplatin was low in our group of patients.

• Authors: W Stöhr, T Langer, A Kremers, I Brecht, J Treuner, A Dinnesen, J D Beck
• Journal: Oncology reports (Oncol Rep) Vol. 12 Issue 4 Pg. 767-71 (Oct 2004) ISSN: 1021-335X [Print] Greece
• PMID: 15375498 (Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• Carboplatin

Topics

• Adolescent
• Adult
• Antineoplastic Agents (adverse effects)
• Audiometry
• Carboplatin (adverse effects)
• Child
• Hearing Loss (etiology)
• Humans
• Incidence
• Prospective Studies
• Sarcoma (complications, drug therapy)